Interactions between drugs and devices: Experimental and clinical studies

https://doi.org/10.1016/0002-8703(94)90076-0Get rights and content

Abstract

It is important to understand the potential interactions between the implantable cardioverter defibrillator (ICD) and antiarrhythmic therapy in patients who receive pharmacologic therapy as an adjunct to ICD therapy. In our cohort of 101 patients, antiarrhythmic agents were prescribed in 67% of the patients during long-term therapy for the following reasons: to suppress ventricular tachycardia/ventricular fibrillation episodes (50%), to lower the rate of ventricular tachycardia (19%), to prevent supraventricular tachyarrhythmia (21%), and for other reasons (10%). The potential influence of antiarrhythmic drugs on the defibrillation threshold (DFT) is the most important issue. In animal studies lidocaine increased the DFT in a dose-dependent manner. Quinidine, procainamide, propafenone, and flecainide did not affect the DFT or, in some cases, led to a small increase. Sotalol even decreased the energy requirements for internal defibrillation. In a prospective investigation we were able to document a significant increase of DFT (from 14.1 + 3.0 to 20.9 + 5.4 J, p < 0.001) by the use of amiodarone (400 mg/day), whereas this effect was not found in patients who received mexiletine (720 mg/day). In conclusion, the DFT or the safety margin for defibrillation should be known before antiarrhythmic agents are administered to patients with an ICD. In case of a small safety margin, the DFT should be reassessed after antiarrhythmic drug therapy is begun.

References (34)

  • T Guarnieri et al.

    Success of chronic defibrillation and the role of antiarrhythmic drugs with the automatic implantable cardioverter/defibrillator

    Am J Cardiol

    (1987)
  • DS Echt et al.

    Clinical experience, complications, and survival in 70 patients with the automatic implantable cardioverter/defibrillator

    Circulation

    (1985)
  • D Wietholt et al.

    Therapie ventrikulärer Tachyarrhythmien mit implantierbaren Kardioverter/Defibrillatoren—Sterblichkeit und Komplikationen bei der Verwendung epikardialer Elektroden

    Z Kardiol

    (1983)
  • WH Kou et al.

    Effect of antiarrhythmic drug therapy on the incidence of shocks in patients who receive an implantable cardioverter defibrillator after a single episode of sustained ventricular tachycardia/fibrillation

    PACE

    (1991)
  • M Fromer et al.

    Efficacy of automatic multimodal device therapy for ventricular tachyarrhythmias as delivered by a new implantable pacing cardioverter-defibrillator

    Circulation

    (1992)
  • CF Babbs

    Alteration of defibrillation threshold by antiarrhythmic drugs: a theoretical frame work

    Crit Care Med

    (1985)
  • DS Echt et al.

    Evaluation of antiarrhythmic drugs on defibrillation energy requirements in dogs: sodium channel block and action potential prolongation

    Circulation

    (1989)
  • Cited by (0)

    View full text